NCT06374901View on ClinicalTrials.gov

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
Gastric Cancer
Interventions
DRUG

Tislelizumab

Preoperative treatment with Tislelizumab

DRUG

SOX/XELOX

Preoperative treatment with SOX/XELOX

Trial Locations (1)

Unknown

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou

All Listed Sponsors
collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

lead

Xiangdong Cheng

OTHER

NCT06374901 - Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. | Biotech Hunter | Biotech Hunter